메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved LEROCHOL™ (lerodalcibep-liga) injection from LIB Therapeutics, for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
- 김갑성 기자
- 2025-12-17 16:10
Next-Gen Omega-3 Solution: infinityseek Unveils Revolutionary Longevity Solution at BioST 2025 SG

[ 메디채널 김갑성 기자 ] Highlighting advances in vascular aging research and microalgae-based Omega-3 innovation SINGAPORE, Dec. 17, 2025 -- The 5th World Biological Science and Technology Conference 2025 Singapore (BioST 2025 SG) opened in Singapore, bringing together leading researchers and industry experts from the global biotechnology sector. The pioneer longevity brand infinityseek was invited to participate in the event, where it formally unveiled its groundbreaking anti-aging solution. The brand's research on vascular aging mechanisms drew strong interest from conference partic
- 김갑성 기자
- 2025-12-17 14:47
BioTec Sets New Market Standards with Fusion-Based Bio Solutions, Aiming for Global Expansion

SEOUL, South Korea, Dec. 17, 2025 -- BioTec's new releases are attracting attention as technology-fusion solutions rarely seen in the current market. The company's supplement developed with processed sulfur and microbial fermentation offers improved gut health and immune support for livestock and companion animals. Meanwhile, the ORP-reducing antioxidant salt provides differentiated functional benefits compared to standard refined salt, introducing a new paradigm in the functional food market. One of the key advantages of these solutions is their ability to integrate seamlessly into ex
- 김갑성 기자
- 2025-12-17 12:10
ASG Receives U.S. FDA IND Approval to Initiate Phase 1 Clinical Trial of the Lead Drug Beta1 for Male Erectile Dysfunction

TAIPEI, Dec. 17, 2025 -- Asia Scientific Global Inc. (ASG), a leader in the research and development of novel inhaled drugs, today announced that its lead product, Beta1, has received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA). Beta1 is currently the only inhaled investigational therapy for male erectile dysfunction to have received such approval and prepared to enter clinical trial. The FDA's clearance underscores ASG's capabilities in drug development and manufacturing technologies. ASG plans to initiate a Phase 1 clinical trial in
- 김갑성 기자
- 2025-12-17 11:30
3 in 4 Asia Pacific Entrepreneurs Anticipate Economic Gains Next Year - Herbalife Survey

HONG KONG, Dec. 17, 2025 -- Herbalife, a premier health and wellness company, community and platform, today released findings from its Asia Pacific (APAC) Health and Economic Empowerment Survey 2025. The findings revealed strong economic optimism among entrepreneurs, with three in four (74%) expecting their economic well-being to improve in the next 12 months, compared to half (48%) of non-entrepreneurs sharing the same outlook. The survey also highlighted significantly higher levels of economic and health empowerment levels among entrepreneurs versus non-entrepreneurs in the r
- 황정호 기자
- 2025-12-17 11:00
Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 17, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory diffuse l
- 김갑성 기자
- 2025-12-17 09:00
Robotware.ai Advances AI Poultry Disease Detection PoC in Malaysia with SDEC

KUALA LUMPUR, Malaysia, Dec. 17, 2025 -- Robotware.ai , a Korea-based artificial intelligence company specializing in livestock intelligence solutions, is advancing its proof-of-concept (PoC) deployment in Malaysia in collaboration with Sarawak Digital Economy Corporation (SDEC) , following the successful implementation of its system at local poultry farms. The ongoing PoC is focused on validating the real-world performance of Robotware.ai's AI-powered poultry disease detection technology under live farm operating conditions. The initiative aligns with Malaysia's efforts to moderniz
- 황정호 기자
- 2025-12-17 09:00
Aussie medtech Ferronova raises another $6 million to advance image-guided cancer surgery

ADELAIDE, Australia, Dec. 17, 2025 -- Australian company Ferronova has raised a further $6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence following surgery. Ferronova's super-paramagnetic iron oxide nanoparticles bind to cells found in lymph nodes which aim to enable identification of tissue that could contain cancerous cells. The technology aims to support more informed surgical decision-making and address the problem that cancer cells are oft
- 김갑성 기자
- 2025-12-17 08:30
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 17, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery pro
- 김갑성 기자
- 2025-12-17 08:04
Jiaying Pharmaceutical: A New Pathway for the Industrialization of Century-Old Hakka Medicine

HONG KONG, Dec. 17, 2025 -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Pharmaceutical Co., Ltd. made a brilliant appearance with its star products, including Double-ingredient Throat Wind Relief Powder, Solid Essence Ginseng and Antler Pill, and Borneol Ointment, showcasing to the world the unique charm of Hakka medicine. Amid the wave of globalization, traditional Chi
- 김갑성 기자
- 2025-12-17 08:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 05시 00분